Efforts will use the firm’s proteomics platform with an initial focus on brain cancer.

Calibrant Biosystems inked a CRADA with the Armed Forces Institute of Pathology (AFIP) to use its Gemini™ proteomics platform in the discovery and development of protein biomarkers. The partners will first conduct research in the area of brain cancer.

AFIP’s tissue microarray laboratory will produce standard and custom tissue microarrays according to Calibrant’s specifications. The company’s technologies will be used to evaluate and validate protein markers for a variety of major, unmet medical needs. Gemini provides the ability to comparatively map protein networks between different cell types within a single tissue section, according to the company.

“Working in partnership with the AFIP via this CRADA offers an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples,” says Michael L. Salgaller, Ph.D., COO at Calibrant.

“This collaboration should expedite the search for novel markers or sets of markers of disease, permitting more sensitive and targeted detection, diagnosis, and prognosis,” adds Satya Saxena, Ph.D., vp for research.

Next articleMacroGenics Buys Raven Biotechnologies to Enhance Oncology Discovery Efforts